News Releases

News and information from The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society Statement on COVID-19 Vaccine Distribution

At The Leukemia & Lymphoma Society (LLS), we hear from blood cancer patients and caregivers each day about the profound effects of the COVID-19 pandemic on their cancer care, treatment, and daily lives. As a patient-focused leader in the scientific and medical community, we are encouraged by the U.S. Food & Drug Administration (FDA) decision to grant emergency use authorization (EUA) to the first COVID-19 vac...

Collaboration Driving Progress: LLS Forms Alliances with Leading Cancer Institutions and Foundations to Co-Fund nearly $17 million in New Research Grants

Rye Brook, NY (December 14, 2020) – As the world confronts a viral pandemic not seen in the past 100 years, the reverberations are being felt across every sector, from healthcare to the economy, education, business and science, including the blood cancer community. Blood cancers don’t stop for the Covid-19 virus and the urgent need for collaboration to address these challenges has never been starker. In respon...

LLS Statement on Oral Arguments in California v. Texas

Rye Brook, NY (November 9, 2020) – This week, the Supreme Court of the United States hears oral arguments in California v. Texas, the case challenging the Affordable Care Act. The following is a statement from The Leukemia & Lymphoma Society’s Chief Medical Officer Gwen Nichols, M.D.: "For more than a decade, cancer patients have relied on the vital protections the Affordable Care Ac...

The Hairy Cell Leukemia Foundation and The Leukemia & Lymphoma Society Join Forces to Find New Therapies for Patients with this Rare Blood Cancer

New York, NY and Rye Brook, NY (November 2, 2020) - The Hairy Cell Leukemia Foundation (HCLF) and The Leukemia & Lymphoma Society (LLS) announced today they are teaming up to support a research grants program of up to $10 million over five years, to build a more comprehensive understanding of hairy cell leukemia (HCL), develop better therapies and optimize outcomes for patients with HCL. The two organizations ...

Study in Nature Medicine Shows Superior Outcomes for Patients in LLS's Paradigm-Shifting Beat AML Clinical Trial

Rye Brook, NY (Monday, October 26, 2020) - Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal. The Beat AML trial achieved its prim...

33 Organizations Representing Millions of Patients Urge Policymakers to Adopt “Patient-First” Policy Agenda

October 13, 2020 – A coalition of 33 organizations representing millions of people with pre-existing conditions launched an unprecedented effort today by releasing their top priorities for the next Administration. The report elevates the collective voices of patients and urges elected officials to ensure all people living in the United States, including those with pre-existing conditions, have access to adequate an...

LLS and Burlington Stores Celebrate 19 Years of Partnership in the Fight Against Blood Cancer

Rye Brook, NY, September 24, 2020 – The Leukemia & Lymphoma Society (LLS), the world's largest nonprofit dedicated to fighting blood cancer, and the national off-price retailer, Burlington Stores, team up for the 19th consecutive year to raise critical funds for lifesaving research and cancer treatments. This year, funds raised in all Burlington store locations nationwide will not only support LLS’s...

The Leukemia & Lymphoma Society Launches First Clinical Trial Specifically for Blood Cancer Patients with COVID-19

Rye Brook, NY (Wednesday, Sept. 9, 2020) - With studies showing between 30-60% of blood cancer patients at risk of death if infected with the COVID-19 virus compared to patients who are cancer-free, The Leukemia & Lymphoma Society (LLS) announced today it is launching the first clinical trial dedicated solely to this most vulnerable population.   This trial (LLS Protocol Number: BAML-16-001-COV1) will tes...

Pages

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.
An LLS representative will respond as soon as possible.